Vol 1, No 4 (2010)
Review paper
Published online: 2010-11-24
Monoclonal antibodies anti-CD20 in the therapy of aggressive lymphomas
Hematologia 2010;1(4):342-351.
Abstract
Introduction of monoclonal antibodies to the therapy of non-Hodgkin lymphoma (NHL) was
a milestone that changed the approach to the treatment of this group of malignancies. High
expression of CD19, CD20, CD22 on B-cell surface makes them targetable with this class of
antineoplastic agents. Monoclonal antibodies allow selective targeting of lymphoma cells expressing
the cognate antigen, with only limited toxicity to healthy tissues and organs. Monoclonal
antibody targeting CD20 has accumulated the most extensive volume of clinical evidence. This
article provides a critical review summarizing its applications in aggressive NHL.
Hematologia 2010; 1, 4: 342-351
Hematologia 2010; 1, 4: 342-351
Keywords: diffuse large B cell lymphomaBurkitt’s lymphomalymphoblastic lymphomamonoclonal antibodies